To highlight the state of the art and current outlook on asthma treatment adherence, beginning with the World Allergy Organization’s ‘Manifesto on Adherence to Asthma Treatment in Respiratory Allergy,’ Allergic Rhinitis and Its Impact on Asthma and Global Allergy, Asthma European Network, and Interasma. Adherence to pharmacological asthma therapies is known to be low: around half of individuals who have been prescribed long-term therapy are nonadherent at least some of the time. Noncompliance is linked to poor asthma control, poor health outcomes, and higher expenditures. Suboptimal adherence can be attributed to a variety of factors, including individuals, treatment and asthma characteristics, the physician–patient interaction, and healthcare resources and facilities.
Given the multidimensional nature of adherence, no single intervention or strategy can improve it in and of itself; however, all players involved in the process are encouraged to collaborate to develop a combined action plan based on the patient’s complexity.
